2021-01-04,b'$KALA #Kala Pharmaceuticals Weekly Symphony Health Estimates for INVELTYS\xe2\x84\xa2: [...] https://t.co/Yuio20Z04w #equity #stocks https://t.co/W3NXoggeYi'
2021-01-03,"b'Evening Most Tweeted Small Caps, check out Gambiste Top 10: $IDEX $MWK $UUUU $GNUS $BNGO $SNDL $PROS $KALA $AFMD https://t.co/k3uyuEbRpJ'"
2021-01-03,b'@Phoenix3million $KALA has truly been one of the most disappointing stocks I own.'
2021-01-03,"b'RT @Phoenix3million: $kala for a down beaten stock - it sure gets a lot of love for a buyout... If we are going to get a BO, it needs to be\xe2\x80\xa6'"
2021-01-03,"b'$kala for a down beaten stock - it sure gets a lot of love for a buyout... If we are going to get a BO, it needs to be a lot quieter, lower volume, and just happen on a mid day one week... {I am long ... but no time frame for a BO}'"
2021-01-03,"b'@pawcio2009 My 5 largest positions are all well represented: $ONCT, $KPTI, $KALA, $EVFM, $PAVM. The next ones I have also in the list $SIOX, $ATHX, $ATNM, $SCYX, $ANIP. My positions not on the list: $VTGN, $ASMB, $AVXL.'"
2021-01-03,"b'$KALA enters a Downtrend because Momentum Indicator dropped below the 0 level on December 28, 2020. View odds for this and other indicators: https://t.co/QVW6Zy0gro #KalaPharmaceuticals #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/Ih0bXo40bU'"
2021-01-03,b'@DolphfredC @Molino70577916 @JRambo0810 I left about 10k $coty  shares and will add more on dips. I\xe2\x80\x99m heavy in biotech now $kpti $kala $nmtr $itrm $sgmo $phas and many many others'
2021-01-03,"b'@funstocks1 @pawcio2009 Same here re $ONCT. I thought seriously about $GTHX, $KALA, &amp; especially lottery tic $ANVS.'"
2021-01-03,b'@lblegend33 Nothing for $KALA?'
2021-01-03,"b'RT @bUrRpPPP: $KALA RAPID MARKET UPTAKE! \nPrior to EYSUVIS, there were no FDA-approved ocular corticosteroids for the treatment of dry eye\xe2\x80\xa6'"
2021-01-03,"b'$KALA RAPID MARKET UPTAKE! \nPrior to EYSUVIS, there were no FDA-approved ocular corticosteroids for the treatment of dry eye disease. Analyst reports suggest Eysuvis\xe2\x80\x99 approval is likely and forecast strong market uptake among untreated DES patients with acute exacerbations.'"
2021-01-03,"b'$KALA Dry eye disease (DED), or keratoconjunctivitis sicca, is one of the most common complaints that eye care practitioners face in their practice.1 In fact, dry eye is the second most common reason patients come in to seek eye care.\n\n https://t.co/iiQNrkQYoG'"
2021-01-03,b'RT @bUrRpPPP: $KALA $NVS The Xiidra ads and tv commercials have to be changed to reflect that Xiidra is NO longer the only FDA approved dru\xe2\x80\xa6'
2021-01-03,"b'$KALA $NVS   Here is yet another article about how Dr\'s use a combination therapy for their patients. They start with an ""off label"" steroid because Eysuvis was not approved yet. Then have patients switch to Restasis or Xiidra... \nhttps://t.co/7jxD03gOx3'"
2021-01-03,"b'$KALA $NVA So there are just 2 FDA approved drugs for the ""signs and symptoms"" of DED.  Big Pharma priced the slow acting Xiidra at $4b... So what will Big Pharma price Fast acting Eysuvis at?  But wait there\'s more!...Eysuvis is the only FDA approved steroid for DED....'"
2021-01-03,"b'$KALA $NVS The Xiidra ads and tv commercials have to be changed to reflect that Xiidra is NO longer the only FDA approved drug for the ""signs and symptoms"" ..I have sent emails to NVS with no replies...but I have not seen a TV ad since New year.  \n\nhttps://t.co/VfmNDoBKwE'"
2021-01-03,b'$KALA https://t.co/9qmu5kPs8e Kala Pharmaceuticals Inc The AI foretells the value of this company won t see its price moving much shortly and will have a negative trend in the upcoming months #investing #trading #trader'
2021-01-03,"b'RT @bUrRpPPP: $KALA $NVS  Novartis took the leap $5B  Xiidra BO.  Said they want to be the ""leader"" in front of eye care. Well you can\'t do\xe2\x80\xa6'"
2021-01-03,"b'$IDEX is No 1 today:  \n\nEvening Most Tweeted Small Caps, check out Gambiste Top 10: $IDEX $BNGO $SMMC $SNDL $KALA $UNFI $MWK $uuuu $gnus https://t.co/DJgv2RHThP'"
2021-01-02,"b'Evening Most Tweeted Small Caps, check out Gambiste Top 10: $IDEX $BNGO $SMMC $SNDL $KALA $UNFI $MWK $uuuu $gnus https://t.co/k3uyuEbRpJ'"
2021-01-02,b'RT @nalyticsatwork: @topologic_apple @egelandd @bUrRpPPP Agree on all points. Buyout price tag and timing will depend on how rapidly their\xe2\x80\xa6'
2021-01-02,"b'@MoneyTrails9 @ThomasPhilipp6 @TonyorAnthony69 @sunrgu @Jessecdghi Other existing ophtalmic corticosteroids (which are more fast acting than cyclosporones, and see also $AUPH fail in dry eye...), are being used but dont have $KALA label nor its proprietary absorption tech + are not even much cheaper, so doctors will prescribe on-label.'"
2021-01-02,"b'RT @topologic_apple: @MoneyTrails9 @ThomasPhilipp6 @TonyorAnthony69 @sunrgu @Jessecdghi Even with better long term cyclosporine treatments,\xe2\x80\xa6'"
2021-01-02,b'RT @topologic_apple: @MoneyTrails9 @ThomasPhilipp6 @TonyorAnthony69 @sunrgu @Jessecdghi Cyclosporines are slow acting and have weak activit\xe2\x80\xa6'
2021-01-02,"b'@MoneyTrails9 @ThomasPhilipp6 @TonyorAnthony69 @sunrgu @Jessecdghi Even with better long term cyclosporine treatments, short term corticosteroids will be used and here $KALA is the only one. $OCUL is more a competitor for restasis/xiidra and most patients dont even benefit from those. $KALA sales will be very good imho.'"
2021-01-02,"b'@MoneyTrails9 @ThomasPhilipp6 @TonyorAnthony69 @sunrgu @Jessecdghi Cyclosporines are slow acting and have weak activity in dry eye (restasis was rejected in EU for lack of efficacy). $OCUL is years away, assuming trials are successful + not even a competitor for $KALA as Eysuvis can be taken in combination with cyclosporine to manage flareups.'"
2021-01-02,b'$kala just as fyi.. that sub 4 on 2 Jan 2020 went up to $7.5+ in first 3 weeks of 2020.  80-90% rise... things can change quickly in bio-land.  needs benign macro / mkt however.  I fully expect 2021 is even a better year than 70% +'
2021-01-02,"b'$kala I think all these posts about how Kala sucked or sucks is forgetting the FACT that that pps was sub $4 in Jan 2020 and on 31 Dec 2020, @ 6.78, the stock went up 70%~ in 12 months.  When have we whined and complained about a 70% rise in stock?  too impatient i think'"
2021-01-02,"b'$KALA enters a Downtrend because Momentum Indicator dropped below the 0 level on December 28, 2020. View odds for this and other indicators: https://t.co/2iNyiQbWmh #KalaPharmaceuticals #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/H0K1onMVd8'"
2021-01-02,b'@egelandd @CDNGreenTrader Holding a good few $auph $gthx $kala and $adms. Daniel any thoughts on adms?'
2021-01-02,b'@egelandd Thank you for continuing to share your thoughts and dd on these gems.\n\nTook a position in $GTHX a while back and in $KALA last week.'
2021-01-02,b'@MoneyTrails9 @TonyorAnthony69 @sunrgu @Jessecdghi Im long $KALA  too.  But i compare it with $AVDL.  RA was invested in with good size. But no BO there and $AXSM with a better product in narcolepsy.  And RA is no more invested in $AVDL.'
2021-01-02,b'@TonyorAnthony69 @sunrgu @ThomasPhilipp6 @Jessecdghi Most of the holders in $kala are in it for a BO which i think wont happen  imo'
2021-01-02,"b""@MikeP15938157 @MidasMulligan6 @Jessecdghi $UROV buyout in November, 2 months before drug launch. Spent most of 2020 hiring commerical team just like $KALA. Won't be surprised to see a buyout early this year."""
2021-01-02,b'@topologic_apple @egelandd @bUrRpPPP Agree on all points. Buyout price tag and timing will depend on how rapidly their very experienced sales force can educate eyedocs. My price target for $kala is $53 to $71. https://t.co/2Jio8QDM0u'
2021-01-02,"b""@TonyorAnthony69 @sunrgu @ThomasPhilipp6 @Jessecdghi Don't get me wrong im long $kala with a full position because i think it's truly undervalued sub 7$ , im thinking out loud and sharing my view of why i think its being a terd"""
2021-01-02,"b""@sunrgu @ThomasPhilipp6 @Jessecdghi You need to think about 10+ years from now who will dominate the market , down the road  it'll be $ocul without a shadow of a doubt \n\nThats why i think $kala s price has been in a downtrend for quite some time , $kala has the upper hand now but in a few years it will be crushed"""
2021-01-02,"b""@Jessecdghi Maybe big pharma will put there eyes on $ocul to snatch it up rather than $kala  since it's the better investment down the road"""
2021-01-02,"b'RT @bUrRpPPP: $KALA $NVS  Novartis took the leap $5B  Xiidra BO.  Said they want to be the ""leader"" in front of eye care. Well you can\'t do\xe2\x80\xa6'"
2021-01-02,"b'$KALA is today ranked #4 in the Daily Gambiste Small Cap rating. Kala Pharmaceuticals, Inc. - Common Stock is today top rated. Check the full Gambiste long term ratings here: https://t.co/RA0LXyNU1n'"
2021-01-02,"b'adding $DM to my 2021 list of stocks to accumulate.  $LGVW $NNOX $PLTR also on that list. \n\n$KALA $KPTI $IMUX on the pound the table buy list at these price levels.  plenty other bios to list, but saving for anther post this weekend.'"
2021-01-02,"b""@Jessecdghi $kala  i think the reason why the stock is acting so poorly regardless of all the catalyst's / market price not reflecting the true value of the company is that there might be a new competitor joining the field = $ocul"""
2021-01-02,"b""RT @MidasMulligan6: @MikeP15938157 @Jessecdghi All fair points but more than priced into $KALA despite cash through Q3 '22 without EysuVIS\xe2\x80\xa6"""
2021-01-02,"b'Midday Most Tweeted Small Caps, check out Gambiste Top 10: $IDEX $BNGO $SMMC $KALA $SNDL $UNFI $MWK $SFT $uuuu https://t.co/k3uyuEbRpJ'"
2021-01-02,"b""@MikeP15938157 @Jessecdghi All fair points but more than priced into $KALA despite cash through Q3 '22 without EysuVIS Rev so minimal dilution risk.  RA likely thinks this asset is worth &gt;$3-4B which means stock price never supported a BO with normal premium (&lt;150%). Even with risks, valuation is so stupid"""
2021-01-02,"b'@MikeP15938157 @Jessecdghi ""least probability of success"" - the risk from the pandemic is to NEAR-TERM revenue, not to PEAK REVENUE in 2030+ on which a BO of $KALA would be based. Who cares if the roll-out is a bit slow. What matters is peak sales estimates are still just as rosy. Thanks for cheap shares.'"
2021-01-02,"b'RT @bUrRpPPP: $KALA Must read!  Newest presentation/ slides for Eysuvis, Inveltys and Kala\'s patented  drug delivery technology ""AMPPLIFY""\xe2\x80\xa6'"
2021-01-02,b'RT @bUrRpPPP: $KALA Big Pharm priced Restasis and Xiidra @ $3-4B each in recent buyouts. Now there is Eysuvis which is the fastest acting F\xe2\x80\xa6'
2021-01-02,"b'$KALA Must read!  Newest presentation/ slides for Eysuvis, Inveltys and Kala\'s patented  drug delivery technology ""AMPPLIFY"" \n\nhttps://t.co/rSajR6m0mY'"
2021-01-02,b'$KALA Patients suffer median 5.5  flare episodes per year . 330 million treatable flare days in the US alone each year. Eye care professionals frustrated with current treatments. Eye care professionals per survey intend to use Eysuvis across vast majority of patients they treat'
2021-01-02,b'$KALA No prior FDA approved option for short term treatment of signs and symptoms of DED. Over 17 million patients diagnosed and currently under care of opthalmologist or optometrist. 75% of these patients have never tried a prescription therapy.'
2021-01-02,"b'$KALA Big Pharm priced Restasis and Xiidra @ $3-4B each in recent buyouts. Now there is Eysuvis which is the fastest acting FDA approved RX for DED. Yet $KALA M/C is just $380M with $150M cash. So the ""market"" wants you to believe Eysuvis is only worth $250M?  Huge run coming!'"
2021-01-02,"b'RT @bUrRpPPP: $KALA $NVS  Novartis took the leap $5B  Xiidra BO.  Said they want to be the ""leader"" in front of eye care. Well you can\'t do\xe2\x80\xa6'"
2021-01-02,"b'RT @bUrRpPPP: $KALA $NVS  Novartis took the leap $5B  Xiidra BO.  Said they want to be the ""leader"" in front of eye care. Well you can\'t do\xe2\x80\xa6'"
2021-01-02,"b'RT @bUrRpPPP: $KALA $NVS  Novartis took the leap $5B  Xiidra BO.  Said they want to be the ""leader"" in front of eye care. Well you can\'t do\xe2\x80\xa6'"
2021-01-02,"b'$KALA enters a Downtrend as Momentum Indicator dropped below the 0 level on December 28, 2020. View odds for this and other indicators: https://t.co/jYG5uwUwEd #KalaPharmaceuticals #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/2Jp5DCklHZ'"
2021-01-01,b'RT @blippd: Great thread for sourcing new ideas. A few of my top holdings seem to be popular picks - $KALA and $ONCT so agree with those bu\xe2\x80\xa6'
2021-01-01,b'RT @blippd: Great thread for sourcing new ideas. A few of my top holdings seem to be popular picks - $KALA and $ONCT so agree with those bu\xe2\x80\xa6'
2021-01-01,b'Great thread for sourcing new ideas. A few of my top holdings seem to be popular picks - $KALA and $ONCT so agree with those but to be different I\xe2\x80\x99m going with:\n\n$INMB\n$70 - guessing roughly $1B takeout by BP in 2021 \n#2021biobuyout https://t.co/yvtpu426ls'
2021-01-01,"b""$KALA $NVS  Kala's patented AMPPLIFY delivery technology is key here. Cutting thru the mucus barrier is what makes BOTH of Kala's FDA approved eye RX so effective and $NVS can't be the leader without out AMPPLIFY...read all about it here. \nhttps://t.co/qTQMDm1WV3"""
2021-01-01,"b'$KALA There are only 3 FDA approved RX for Dry eye . Restasis, Xiidra and Eysuvis\n\nOnly one can be used in combination with the other 2.  Yes Eysuvis\n\nOnly one has not been bought out. Yes Eysuvis\n\nOnly one works in days vs weeks. Yes Eysuvis'"
2021-01-01,"b'$KALA ""EYSUVIS will allow patients to treat their DED as they have always wanted....as needed...they want their medicine to work quickly and discontinue once they feel better...EYSUVIS is the only med that does want the patient has always wanted!""'"
2021-01-01,"b'$KALA ""we are well positioned to  offer the market what it\'s been missing for a really long time!"" \n""A fast acting therapy that is going to get patients felling better in just a few days!"" \n\nMin 13   \n\nhttps://t.co/kq0ees8n3h'"
2021-01-01,"b'$KALA $NVS  Novartis took the leap $5B  Xiidra BO.  Said they want to be the ""leader"" in front of eye care. Well you can\'t do that with out Eysuvis. Xiidra will be second line VS fast acting EYSUVIS will become first line SOC... Buyout $2B =$35pps and get Inveltys +140M cash too!'"
2021-01-01,"b""$KALA  So lets get crazy with napkin math.\n17m diagnosed with DED so lets say we get just 5% or 850,000 \n\navg 3 cycles a year @$450 treatment =$1,350\n\n$1,350x 850,000 patients $1.2 B revs per year.....as you can see it's not too complicated. \n\nBuyout coming!"""
2021-01-01,"b'@egelandd @SurrogateCap @SupesesClub $KALA 150M cash w/ runway until 3rd quarter 2022 (just with Inveltys sales), Eysuvis imminent official launch in January, even if Eysuvis does not sell a single prescription, there is not much downside from these levels. Screaming buy.'"
2021-01-01,"b""RT @Phoenix3million: I only usually keep 5 tickers for 2021 (core position + trading pos).  here's my picks - $cala, $cris, $kala, $kpti, $\xe2\x80\xa6"""
2021-01-01,b'Torn between using my $600 stimulus to buy a new Driver \xf0\x9f\x8f\x8c\xef\xb8\x8f\xe2\x80\x8d\xe2\x99\x82\xef\xb8\x8f or buying more stocks $PCPL $FUBO $BNGO $FSR $KALA $ATNF $GNOG $RKT $IPOC $GHIV'
2021-01-01,"b""RT @Phoenix3million: I only usually keep 5 tickers for 2021 (core position + trading pos).  here's my picks - $cala, $cris, $kala, $kpti, $\xe2\x80\xa6"""
2021-01-01,"b""WHAT'S UP WITH $FBIO $LPTX $KALA $OCGN??? \xf0\x9f\x92\xb0\xf0\x9f\x92\xb0\xf0\x9f\x92\xb0\xf0\x9f\x9a\x80\xf0\x9f\x9a\x80\xf0\x9f\x9a\x80\xf0\x9f\x9a\x80\xf0\x9f\x9a\x80"""
2021-01-01,b'@egelandd @Phoenix3million One of my friends with deep bio background also thinks $kala should/would be bo.'
2021-01-01,b'RT @wshao8: @egelandd @Phoenix3million happy new year. Do you also like $cala? It is not $kala :-)'
2021-01-01,b'@egelandd @Phoenix3million happy new year. Do you also like $cala? It is not $kala :-)'
2021-01-01,"b""RT @Phoenix3million: I only usually keep 5 tickers for 2021 (core position + trading pos).  here's my picks - $cala, $cris, $kala, $kpti, $\xe2\x80\xa6"""
2021-01-01,"b""RT @Phoenix3million: I only usually keep 5 tickers for 2021 (core position + trading pos).  here's my picks - $cala, $cris, $kala, $kpti, $\xe2\x80\xa6"""
2021-01-01,"b""RT @Phoenix3million: I only usually keep 5 tickers for 2021 (core position + trading pos).  here's my picks - $cala, $cris, $kala, $kpti, $\xe2\x80\xa6"""
2021-01-01,"b""RT @Phoenix3million: I only usually keep 5 tickers for 2021 (core position + trading pos).  here's my picks - $cala, $cris, $kala, $kpti, $\xe2\x80\xa6"""
2021-01-01,"b""Happy new year all. First full year of investing and 85.8% return for the year. I'm not sure it's a good start to investing. It just breeds over confidence and greed. :) \n\nThank you $ocul $psnl $myov $alxn and all the others.\n\nLook forward to 2021 of $ocul $KPTI $KALA and more!"""
2020-12-31,"b""RT @Phoenix3million: I only usually keep 5 tickers for 2021 (core position + trading pos).  here's my picks - $cala, $cris, $kala, $kpti, $\xe2\x80\xa6"""
2020-12-31,"b'$cala $cris, $kala, $kpti, $gthx  I meant I try to keep 5 picks for the duration of the year vs investing too many tickers.  Focus on quality tickers where mkt has not fully appreciated yet, and be patient'"
2020-12-31,"b""I only usually keep 5 tickers for 2021 (core position + trading pos).  here's my picks - $cala, $cris, $kala, $kpti, $gthx.  \n1.  CALA (RCC + KEAPSAKE data)\n2.  CRIS (partnership first + BO)\n3.  KALA (A+ CEO w/ M&amp;A exit). \n4.  KPTI (approved drugs, $1B MC cheap).  BO\n5.  GTHX"""
2020-12-31,"b'Doubled $KALA long into JPM21, top contender for a buyout'"
2020-12-31,b'RT @Pharmdca: Opening position in $KALA 6.77'
2020-12-31,"b'Opened positions all at current prices $kala pre ipo investor doubled stake at $7.89 $onct half MC cash, $kpti good set of oncology assets.'"
2020-12-31,"b""@Pharmdca $kala is derisked as derisked can be\n\nGood pipeline\n\n2 approved drugs \n\nSales of the drugs + 159 m $ in cash will provide cash runway till 2023\n\nIpo'd at 15 with no drugs\n\nNow sub 7 with 2 approved drugs\n\nThis is bullshit"""
2020-12-31,b'RT @Pharmdca: Opening position in $KALA 6.77'
2020-12-31,b'Just added $kala https://t.co/wkKE19kUVn'
2020-12-31,b'@Pharmdca $KALA should be on everybody\xe2\x80\x99s watchlist.  Good call as usual.  It\xe2\x80\x99s only a matter of time for this one.'
2020-12-31,b'@zeltser22 @Pharmdca Like to see this as well. Have a lot of $KALA into 2021'
2020-12-31,b'Opening position in $KALA 6.77'
2020-12-31,b'It\xe2\x80\x99s a good thing I\xe2\x80\x99ve been short term trading well.  Because my longer term holds have been sucking it up last couple weeks.   At least for now.  On to 2021 ....\n$CAPR \xf0\x9f\xa4\xa2\n$KALA \xf0\x9f\xa4\xa2\nAt least I wasn\xe2\x80\x99t buying heavy volume sell dips in $FUBO.  \xf0\x9f\x98\x82'
2020-12-31,"b'@JonahLupton $kala ? pharmaceutical company, in October the FDA approved a drug for dry eye.  they begin to expand distribution networks, possible buy out or not ... how do you see it?'"
2020-12-31,"b'@egelandd @BioRampCapital @InTheTrenches2 How much leverage does RA have over $KALA regarding whether to sell the company (vs. go it alone)?   Is RA pretty much calling the shots on this, given the board seat and the large ownership %?'"
2020-12-31,b'Now a $kala baggie holder\xe2\x80\xa6\xe2\x80\xa6\xe2\x80\xa6.'
2020-12-31,b'RT @BobMarshall63: FWIW changes in LT account - large positions in order: $TGTX $AXSM $DMTK $IPOC $SGMO $XAIR $BTAI $OCUL $KALA $ONCT $TCON\xe2\x80\xa6'
2020-12-31,"b'Watchlist is the same:  $DKS, $DBX, $FUV, $HBI, $KALA, $ZNGA, $DHI, $SESN\n\nAlso, from my portfolio list, $ON looks to open at its all time highs.\n\nDetail: https://t.co/WPdxqa1Mdj\n\n#Trading #GuidedByFibs'"
2020-12-31,"b""$KALA $AUPH $TRVN $LPCN Q1 Micro caps WINNERS right here! If you're brave enough $SNDL $IBIO $JAGX could turn the heat up as well"""
2020-12-31,b'RT @BobMarshall63: FWIW changes in LT account - large positions in order: $TGTX $AXSM $DMTK $IPOC $SGMO $XAIR $BTAI $OCUL $KALA $ONCT $TCON\xe2\x80\xa6'
2020-12-31,"b'@egelandd @SupesesClub So you just trading $kala, while it\xe2\x80\x99s below its 200 dma - ok, that\xe2\x80\x99s better, not a long term holder in a weak looking stock, great\n\nSame for $kpti?  Just trade it'"
2020-12-31,"b'RT @BioRampCapital: @InTheTrenches2 @egelandd I am long $KALA, this stock is trading at a significant Pandemic to Market Discount. Even if\xe2\x80\xa6'"
2020-12-31,"b'RT @BioRampCapital: @InTheTrenches2 @egelandd I am long $KALA, this stock is trading at a significant Pandemic to Market Discount. Even if\xe2\x80\xa6'"
2020-12-31,"b""@egelandd @Investor2b @biostockguru The difficulty I see with $kala is that they don't have quite the same payer dynamics as $ocul and a sales ramp might be considerably more difficult?"""
2020-12-31,b'RT @biostockguru: Most likely biotech buyout for #2021biobuyout \n\n$ONCT $KALA $TRIL $KPTI'
2020-12-31,"b'$KZIA $KALA $ONCT $KPTI $PHAT are all very very cheap IMO, all for different reasons. Biotech market always offers severely undervalued gems, then suddenly market discovery occurs. See $XENE over last couple of weeks for example of market discovery. Will happen fast.'"
2020-12-31,"b'@InTheTrenches2 @egelandd I am long $KALA, this stock is trading at a significant Pandemic to Market Discount. Even if you think the peak sales is a measly 300 million (worst case scenario) this is super super cheap.'"
2020-12-31,b'@biostockguru $kala  definitely under valued at 385m  market cap with 2 approved drugs'
2020-12-31,b'Most likely biotech buyout for #2021biobuyout \n\n$ONCT $KALA $TRIL $KPTI'
2020-12-31,"b'@egelandd Good points on the setup here, with RA Capital having a significant stake. $KALA'"
2020-12-31,"b""@egelandd Thanks.  I misread your post. I thought you were saying it was in his personal acct.\n\n20% is a big stake, whether it's fund or personal; &amp; RA Capital is HIGHLY respected in the industry...as you say, that's huge.\n\nI'm very long $KALA.  I REALLY appreciate your insights.\nCheers"""
2020-12-31,"b""@egelandd Rajeev didn't buy 6.3M shares of $KALA.  RA Capital bought those shs.  Because RA Capital owns 10M+ (?) shs of KALA (20% of issued), they negotiated a seat on the BOD.  Rajeev is the nominee from RA Capital to take that seat.  Rajeev owns no shares in $KALA for his personal acct."""
2020-12-30,"b'RT @GambisteFinance: Evening Most Tweeted Small Caps, check out Gambiste Top 10: $GEVO $GNUS $kala $PLG $CNCE $etm $MGI $IMMR $clvs https:/\xe2\x80\xa6'"
2020-12-30,"b'Evening Most Tweeted Small Caps, check out Gambiste Top 10: $GEVO $GNUS $kala $PLG $CNCE $etm $MGI $IMMR $clvs https://t.co/k3uyuEbRpJ'"
2020-12-30,b'RT @unusual_whales: $KALA 2021-07-16 C $7.5\n\n\xf0\x9f\x97\x93\xef\xb8\x8f\xf0\x9f\x90\x82\nBid-Ask: $2.05 - $2.3\nInterest: 91\nVolume: 500\nIV: 121.64%\n% Diff: 9.49%\nUnderlying: $6.85\xe2\x80\xa6'
2020-12-30,"b""HAPPY NEW YEAR from Trade Ideas!\nWe're offering you 25% off your 1st month or year of Trade Ideas.\n\n*SALE runs from Wed, Dec-30 through Mon, Dec-04\n\nvia \xe2\x9f\xb6 https://t.co/HTtPehk55I \n( Coupon code is : AULDLANGSYNE25% )\n\n$INO $ARCT $AMC $XSPA $NVTA $RRC $KALA $NAT $EQT $BIGC https://t.co/DWPbZXyv1w"""
2020-12-30,b'@SupesesClub $kala chart looks weak?  Why u like?'
2020-12-30,"b'Afternoon Most Tweeted Small Caps, check out Gambiste Top 10: $GEVO $GNUS $kala $PLG $CNCE $etm $MGI $IMMR $clvs https://t.co/k3uyuEbRpJ'"
2020-12-30,"b'$KALA 2021-07-16 C $7.5\n\n\xf0\x9f\x97\x93\xef\xb8\x8f\xf0\x9f\x90\x82\nBid-Ask: $2.05 - $2.3\nInterest: 91\nVolume: 500\nIV: 121.64%\n% Diff: 9.49%\nUnderlying: $6.85\nDaily $ Volume: $108,750\nSector: Health Technology\n\xf0\x9f\x97\x93\xef\xb8\x8f\xf0\x9f\x90\x82\n\nFind out more at: https://t.co/66RUU9gMq1'"
2020-12-30,"b'$kala is today ranked #5 in the Daily Gambiste Small Cap rating. Kala Pharmaceuticals, Inc. - Common Stock is today top rated. Check the full Gambiste long term ratings here: https://t.co/RA0LXyNU1n'"
2020-12-30,"b""@biostockguru And an imminent catalyst with product launch. Previous guidance from company was by EOY so maybe today or tomorrow! And who cares if launch or the stock drifts into early '21! Going to be a fun '21 regardless! $KALA"""
2020-12-30,"b'Midday Most Tweeted Small Caps, check out Gambiste Top 10: $GEVO $GNUS $etm $IMMR $kala $UUUU $BTBT $clvs $IDEX https://t.co/k3uyuEbRpJ'"
2020-12-30,b'@Pharmdca $kala I jumped out thank god I did'
2020-12-30,b'@BTGPremium $KALA time to jump in?'
2020-12-30,b'$KALA  A few Insider buys would be nice about now.....'
2020-12-30,b'I bit and averaged down slightly on $kala at 6.8'
2020-12-30,b'RT @ms_Amsu: @MelissaLeeCNBC; @Bonawyn @CNBCFastMoney; @GuyAdami  - hello there. novice investor here. Have been researching some stocks an\xe2\x80\xa6'
2020-12-30,b'RT @ms_Amsu: @MelissaLeeCNBC; @Bonawyn @CNBCFastMoney; @GuyAdami  - hello there. novice investor here. Have been researching some stocks an\xe2\x80\xa6'
2020-12-30,b'RT @ms_Amsu: @MelissaLeeCNBC; @Bonawyn @CNBCFastMoney; @GuyAdami  - hello there. novice investor here. Have been researching some stocks an\xe2\x80\xa6'
2020-12-30,b'@egelandd @wshao8 @biostockguru $kala looks sick and may break $6 - why you like it?\nvery weak stock https://t.co/dw8LhpObQA'
2020-12-30,b'@PharmaBoss @egelandd My average in $KALA  is 7.18'
2020-12-30,b'@egelandd Absolutely right - loading both $KALA $GTHX for 2021\nExpect huge upside in both as well as $ONCT $MREO &amp; few others \n\n#opportunity + #patience = \xf0\x9f\x92\xb0\xf0\x9f\x92\xb0'
2020-12-30,"b'Tues (12/29/20) bearish 8/21 EMA X-Over with greatest % below the opening 30-min low &amp; trading range &lt; 20% (Min $5 &amp; Vol 750K, Min Opt Vol 250 in any strike): $SPG $KALA $SLQT $KPTI https://t.co/spNCvxOCan'"
2020-12-30,"b'Tues (12/29/20) X Below 20-Day price channel with greatest % below the opening 30-min low &amp; trading range &lt; 20% (Min $5, Vol 750K, Opt Vol in any strike 250): $KALA https://t.co/8ZPRexX6cP'"
2020-12-30,"b'Added $kala today, made all the sense in the world'"
2020-12-30,"b'RT @Phoenix3million: $gthx Needs a gap down day and pull a hammer - then it RUNS to $24-26 by PDUFA... $kala - this needs a BO - otherwise,\xe2\x80\xa6'"
2020-12-30,b'RT @Kevin_W81: $KALA  joined @lblegend33 \n\nFDA approved October 2020. List price for a 10 mL bottle of EYSUVIS \xf0\x9f\x91\x89\xf0\x9f\x8f\xbc $465\n\n\xf0\x9f\x92\xb0Cash Runway Q3 202\xe2\x80\xa6'
2020-12-30,"b""Q1 naturally offers a lift and I'm ready to go big on $JMIA (February $60) $NIO (Jan at $65)  $PLTR (March $45) $IPOC, $AUPH, $KALA, $LPCN, $TRVN + a few other plays"""
2020-12-30,b'RT @Kevin_W81: $KALA  joined @lblegend33 \n\nFDA approved October 2020. List price for a 10 mL bottle of EYSUVIS \xf0\x9f\x91\x89\xf0\x9f\x8f\xbc $465\n\n\xf0\x9f\x92\xb0Cash Runway Q3 202\xe2\x80\xa6'
2020-12-30,b'RT @Kevin_W81: $KALA  joined @lblegend33 \n\nFDA approved October 2020. List price for a 10 mL bottle of EYSUVIS \xf0\x9f\x91\x89\xf0\x9f\x8f\xbc $465\n\n\xf0\x9f\x92\xb0Cash Runway Q3 202\xe2\x80\xa6'
2020-12-29,"b'Evening Most Tweeted Small Caps, check out Gambiste Top 10: $IDEX $BTBT $CLCT $OCGN $expc $kala $UUUU $ACBI $GEVO https://t.co/k3uyuEbRpJ'"
2020-12-29,"b'$KALA  joined @lblegend33 \n\nFDA approved October 2020. List price for a 10 mL bottle of EYSUVIS \xf0\x9f\x91\x89\xf0\x9f\x8f\xbc $465\n\n\xf0\x9f\x92\xb0Cash Runway Q3 2022. ""KALA expects EYSUVIS revenues will provide additional cash runway""\n\n""As of October 23, the dry eye disease market is at 99% of its pre-COVID levels"" https://t.co/4owgKzOm8m'"
2020-12-29,b'@GaltGhost $KALA Not sure about \xe2\x80\x9c6 months\xe2\x80\x9d. https://t.co/ihTranoRbl'
2020-12-29,b'@perrone_ken Why are you buying $KALA. Will need to raise money withing 6 months.'
2020-12-29,"b'Afternoon Most Tweeted Small Caps, check out Gambiste Top 10: $IDEX $OCGN $CLCT $BTBT $UUUU $kala $GEVO $uavs https://t.co/k3uyuEbRpJ'"
2020-12-29,"b'RT @CapitalMlc: @egelandd solid institutional backing, unusual activity with over 2000 opening contracts in July 15 calls today as well.\n\nS\xe2\x80\xa6'"
2020-12-29,b'Bought a large position in $AMRN here at $4.83/$4.84 and bought back $KALA this afternoon and adding with a $6.73 avg now.  Two names I continue to feel will be sold pretty quickly in 2021.  Taking these into the new year with me.'
2020-12-29,b'$KALA picked a bad week to quit sniffing glue.... https://t.co/4DlC23fXqn'
2020-12-29,b'$KALA \n\nTrading like #buyout news coming \xf0\x9f\x94\x9c \n\nLoading the truck https://t.co/TVcLncceen'
2020-12-29,"b'@TahoeLK I am with you there. I have a semi large position in $KALA, painful to see.  Hope its just some tax harvesting here. May have to add or sell some puts tomorrow to lower cost.'"
2020-12-29,b'RT @TahoeLK: $KALA is trading like a joke. No way someone is buying them out or a successful launch is coming'
2020-12-29,"b""What do we retail don't know about $KALA ?"""
2020-12-29,b'@sunrgu @TahoeLK But could be $OCUL the $KALA killer? Disclaimer: I am long $KALA.'
2020-12-29,b'$KALA  Love this stock...gave me another good reason to drink heavy today!'
2020-12-29,b'$KALA is trading like a joke. No way someone is buying them out or a successful launch is coming'
2020-12-29,"b""RT @Phoenix3million: $kala  July $15 strike calls had 2K+ volume today.. very unusual - anyone catch those at mid day?  it wasn't one trans\xe2\x80\xa6"""
2020-12-29,"b""RT @bUrRpPPP: $KALA same exact selloff happened last week of last year...Then first week of Jan we started the run from $3's to $15.... loo\xe2\x80\xa6"""
2020-12-29,b'Update: it also appears this holds true to the downside as well $KALA getting beat up for what appears to be EOY tax harvesting https://t.co/SDQKlA6PSq'
2020-12-29,"b'Mid-day bearish 8/21 EMA X-Over with greatest % below the opening 30-min low &amp; trading range &lt; 20% (Min $5 &amp; Vol 750K, Min Opt Vol 250 in any strike): $SRNE $DB $KALA $W $CARR $ARCT $RTX $BB https://t.co/liBhXtrNOo'"
2020-12-29,"b'Mid-day X Below 20-Day price channel with greatest % below the opening 30-min low &amp; trading range &lt; 20% (Min $5, Vol 750K, Opt Vol in any strike 250): $CODX $ACB $INO $GOOS $W $ARCT $KALA $CIM https://t.co/IbljoDG9eq'"
2020-12-29,b'#Stocks trading with new monthly lows\n\n$INO $ARCT $AMC $XSPA $NVTA $RRC $KALA $NAT $EQT $BIGC \n\n(+19 more results)  Scan updates every 5 secs.\n#nyse #nasdaq\nhttps://t.co/14VswsoneT'
2020-12-29,b'Added another tier to $KALA swing long. \n\nGood day to take advantage of tax loss selling.'
2020-12-29,"b'Added more $KALA , indiscriminate fire sale on an already heavily undervalued stock'"
2020-12-29,b'Recent $KALA technical alerts: MACD Bearish Signal Line Cross plus 4 more alerts... https://t.co/kFuStlQw9o'
2020-12-29,b'$KALA Retail getting robbed https://t.co/yIBeOBRrLH'
2020-12-29,"b'@WhiteBit6 @thekalacoin Yes, i made 185$ profit in $BTC\n@thekalacoin  $KALA'"
2020-12-29,"b""RT @bUrRpPPP: $KALA same exact selloff happened last week of last year...Then first week of Jan we started the run from $3's to $15.... loo\xe2\x80\xa6"""
2020-12-29,"b'RT @LeeVing10: Remember the $KALA chart breakout lol. Gee, let me draw a really thick trendline that means nothing and then proclaim a brea\xe2\x80\xa6'"
2020-12-29,"b'$kala i guess traders care all about breakouts, charts, etc.. in 20 yrs, i have invested, not traded.  i own a ton of Kala - under water by a few %, but waiting for the big pay day.. not 25c, 50c or $1.  I do monitor technical chart, to see points where i may trade non-core pos. https://t.co/TTv54rtkti'"
2020-12-29,b'$KALA Im hiding under my desk at the moment.... someone let me know when they release launch update....'
2020-12-29,b'$KALA has provided the first non-steroid treatment for dry eye disease - their stock price. \n\nStill long.'
2020-12-29,"b'added more $KALA @ 6,94'"
2020-12-29,"b""$KALA same exact selloff happened last week of last year...Then first week of Jan we started the run from $3's to $15.... look at the chart...."""
2020-12-29,"b""Remember the $KALA chart breakout lol. Gee, let me draw a really thick trendline that means nothing and then proclaim a breakout.  Remember the clowns who post shit like that and file it away for next time. I'm trying to be nice and not call out specific people but it ain't easy"""
2020-12-29,"b'not sure what is ""Santa Claus Rally"" I\'ve got 46 trades and all of them either down significantly or deep in red.  $IBIO, $SLDB, $NIO, $JMIA, $WATT, $AUPH, $TRVN, $KALA, $PIC, $IPOC, $AESE, $FUBO, $ONCT, $DKNG to name a few'"
2020-12-29,"b""$KALA stopped out $6.97 for a -$650 loss or -4%. Will revisit this but for now I'm out as it falls below the $7 line https://t.co/WF51qRxKH0"""
2020-12-29,b'$KALA A gift below $7'
2020-12-29,"b'@Old_Saito @SupesesClub Agree, good point, and great call dumping $KALA at $7.90!'"
2020-12-29,b'$KALA looks like someone exiting not retail sales'
2020-12-29,b'@Nvest_In_You $KALA hot bottom of the box. Can it rebound or go to 6.10'
2020-12-29,"b'@MelissaLeeCNBC; @Bonawyn @CNBCFastMoney; @GuyAdami  - hello there. novice investor here. Have been researching some stocks and am Kindly asking for your feedback on some stocks. Do you consider the following as \xe2\x80\x9cbuys\xe2\x80\x9d - $PFE, $KALA; $NOK; &amp; $ADMA? Thank you and happy new year!'"
2020-12-29,"b'$KALA Hannah from IR dept is tight lipped ...but she did confirm they are ""on track with the schedule previously disclosed""  regarding ""have a full team of 90 representatives onboarded and trained in November and to host a virtual launch meeting in early December."" comments made.'"
2020-12-29,"b'RT @PharmaBoss: $kala something has to be cooking because there has been no communication on the launch since mid November, with launch pla\xe2\x80\xa6'"
2020-12-29,"b'$kala something has to be cooking because there has been no communication on the launch since mid November, with launch planned in December. Big news must be coming in the next 48 hours! \xf0\x9f\x9a\x80 \xf0\x9f\x92\xb0\xf0\x9f\x92\xb5\xf0\x9f\xa4\x91'"
2020-12-29,b'@egelandd @DeepSouthDoctor Why do $kala and $kpti always revert to the mean anytime they go on any sort of run? I\xe2\x80\x99ve never seen two equities have such strong upward resistance.'
2020-12-29,"b""RT @Phoenix3million: $kala  July $15 strike calls had 2K+ volume today.. very unusual - anyone catch those at mid day?  it wasn't one trans\xe2\x80\xa6"""
2020-12-29,"b""$kala  July $15 strike calls had 2K+ volume today.. very unusual - anyone catch those at mid day?  it wasn't one transaction; rather several - but largest one was 1100+ call sweep.  Break even is $16.25ish, $9 higher than current pps."""
2020-12-29,"b'@egelandd solid institutional backing, unusual activity with over 2000 opening contracts in July 15 calls today as well.\n\nShould be getting update on launch shortly.... $KALA'"
2020-12-28,"b'RT @CapitalMlc: @egelandd those form 4s in Oct were all RSU grants, I see no open market purchases....? $KALA'"
2020-12-28,b'Short sale volume(not short interest) for $XOP on 2020-12-24 is 72%. https://t.co/toL92hxcqb $MSFT 34% $EOSE 43% $MBRX 49% $KALA 44%'
2020-12-28,"b'@egelandd those form 4s in Oct were all RSU grants, I see no open market purchases....? $KALA'"
2020-12-28,"b""Ouch! Lost the 50 and 9ema on the daily like magic... At least we're at a long-term support level and still trading in the box...  $KALA https://t.co/DZE2Lpkgxv"""
2020-12-28,"b""$gthx Needs a gap down day and pull a hammer - then it RUNS to $24-26 by PDUFA... $kala - this needs a BO - otherwise, it needs REAL RX # which won't be for a while still, amidst Covid environment.  $KPTI - also needs a BO - all 3 very undervalued"""
2020-12-28,"b'RT @TezosHunter: I really believe this will be a game changer as big as Edo\nNFTs mintery and market for a reasonable price (gas wise), will\xe2\x80\xa6'"
2020-12-28,b'$kala sure seems like MMs are forcing out frustrated retail last few days...'
2020-12-28,"b""I really believe this will be a game changer as big as Edo\nNFTs mintery and market for a reasonable price (gas wise), will bring a lot of artists and devs to Tezos, coming from Ethereum.\nSpecially considering they'll become a DAO with $KALA as a governance token! https://t.co/WtMaE2FTUI"""
2020-12-28,"b""$KALA 2.5M volume  LOD $7.33  someone hell bent on taking this back to $6's"""
2020-12-28,b'Someone is sweeping up $KALA  JULY 21cs at 1.35ish.  \n\nhmmmmmmmmm'
2020-12-28,"b'Short-term, I like:\n$DCTH $EVFM $NVAX $KALA'"
2020-12-28,b'$KALA The algo program on this is working well...heavily shorting last weeks breakout to discourage all retail to sell for a loss...next target is to drive out remaining longs by convincing them something is wrong with endless selling now that this BOT is in full control!'
2020-12-28,b'$KALA Im still here...in my van down by the river...waiting for my day to come! https://t.co/tj5ib8OaRG'
2020-12-28,"b'full position:  $XERS, $ONCT, $KALA'"
2020-12-28,"b'$kala news due any day now. The launch was expected in early December, an update by month end has to come. Where is the communication?'"
2020-12-28,b'RT @semodough: @tun10 $OCUL AMD product most likely makes $KALA obsolete down the road'
2020-12-28,b'@buysidebio Thanks again for $OCUL postings ...been looking @ $KALA \xe2\x80\x94is there a wart there I\xe2\x80\x99m not seeing ? Fda approved treatment and $400m mc?'
2020-12-28,b'$KALA #Kala Pharmaceuticals Weekly Symphony Health Estimates for INVELTYS\xe2\x84\xa2: [...] https://t.co/TxJbzFIojW #equity #stocks https://t.co/VJEtIRcv5S'
2020-12-28,b'$KALA is a holding ive been adding to like crazy.  Large chunk of my long term is sitting in this.'
2020-12-28,"b'Watched the movie #Fatman yesterday.  Had no idea Santa was such a badass.  This current Santa rally I expect to be badass.  With January, as always, being very telling of the year to come. $CVLB $ENSV $CAPR $KALA just a few that will Up my new year. \xf0\x9f\x8e\x85\xf0\x9f\x94\xa5'"
2020-12-28,b'$KALA shows a strong growth in EPS: 27.18%. https://t.co/JBriLNOkB4 https://t.co/pYotCnxkuA'
2020-12-28,b'2020-12-24 Short sale volume (not short interest) for $IPOC is 36%. https://t.co/WcxnedIZFa $NURO 46% $BZUN 60% $KALA 44% $CHEK 51%'
2020-12-27,"b'My watchlist for tomorrow: $DKS, $FUV, $HBI, $KALA, $ZNGA  \n\nFor details see: https://t.co/uOns56HWcj  #trading #GuidedByFibs'"
2020-12-27,b'$AYRO to be featured on Mad Money with Jim Cramer next week gaining nationwide exposure\nhttps://t.co/Mv3xmUJu9A\n\n$KALU $KALTF $KALO $KALA $JW/A $JRVR $JQC $JPS $IVTY $IVC $ITRI $ITNS $ACNNF $VCSY'
2020-12-27,b'@Phoenix3million @birgirm_m @semodough @tun10 Maybe. But is going to be a lot of mileage for $KALA on the same road.'
2020-12-27,b'RT @MarcJacksonLA: $KALA - Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved. https://t.co/PSU35RKLfZ  https://t.\xe2\x80\xa6'
2021-01-08,"b""RT @bUrRpPPP: $KALA All the boxes checked now but one.\n\n\xe2\x9c\x85Top Management\n\xe2\x9c\x852 Approved FDA RX\n\xe2\x9c\x85Huge Market/need\n\xe2\x9c\x85Insurance co's on board\n\xe2\x9c\x85Firs\xe2\x80\xa6"""
2021-01-08,"b'slow day, got my planned $DM buys in at the open and morning hours.  added to the following:\n$IPOF $IPOD (before $IPOE was sent flying)\n$KALA $NPA $GHIV $MGNI (great dip buys here)\nnew position: $JMIA\n\nall smaller buys except $DM, based on what i tweeted out at the open.'"
2021-01-08,b'$KALA Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline https://t.co/oGRdqfl0gv'
2021-01-08,b'@nalyticsatwork @MidasMulligan6 $KALA Whoops....yes Anthem not Aetna...'
2021-01-08,b'$KALA #Kala Pharmaceuticals EYSUVIS\xe2\x84\xa2/DED Launched in U.S.; Strong Cash Position Supports Pipeline Expansion: [...] https://t.co/zoiUMeNwle #equity #stocks https://t.co/JriNQsJ2nS'
2021-01-08,b'$KALA nice article in December that I missed.  In case anyone else missed this was an interesting read and not biased.\n\nhttps://t.co/w03t7QQ70a'
2021-01-07,"b'Evening Most Tweeted Small Caps, check out Gambiste Top 10: $SNDL $IDEX $BNGO $CBAT $OCGN $EBON $GEVO $KALA $UAVS https://t.co/k3uyuEbRpJ'"
2021-01-07,"b""$KALA's price moved below its 50-day Moving Average on December 28, 2020. View odds for this and other indicators: https://t.co/MeRqV4e5X9 #KalaPharmaceuticals #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/8GToiQlIJu"""
2021-01-07,b'Shorted $KALA today on and off over $7. Think the launch gets delayed and this tanks.'
2021-01-07,"b'Afternoon Most Tweeted Small Caps, check out Gambiste Top 10: $SNDL $BNGO $IDEX $CBAT $EBON $GEVO $OCGN $KALA $MWK https://t.co/k3uyuEbRpJ'"
2021-01-07,"b""$KALA just a reminder...Nobody has Kala's Patented AMPPLIFY DRUG DELIVERY TECHNOLOGY...NOBODY!  It's what makes both of KALA FDA approved drugs safer and more effective...  \nhttps://t.co/85pTHcfXr9"""
2021-01-07,b'RT @StockNewsNow: $KALA Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update o\xe2\x80\xa6'
2021-01-07,"b""$KALA Hopefully today is the last day this stock ever see's $6's again...nothing but steady news /progress/updates all year long!"""
2021-01-07,"b'RT @egelandd: Bioland was sleeping on $kala - it was all there: 2 recently approved products, strong leadership w/execs that have proven M&amp;\xe2\x80\xa6'"
2021-01-07,"b""@pawcio2009 thank you for the list\n\n$PAVM $ONCT $AFMD $SIOX $XAIR $PDSB $ADAP $APTO $CRIS $SGMO $TCON $CYCC $LPTX $KALA $TRIL $NWBO $ANVS $KPTI $MREO $PIRS $TGTX $VBIV $XERS $ARWR $ATNM $BCRX $BNGO $EVFM\n\nhttps://t.co/lMqxB0FAUJ\n\n($NWBO doesn't show)"""
2021-01-07,"b""@Eli75NY Yes.  I have two words.   it's $kala"""
2021-01-07,b'$KALA any explanation why all the gains fizzled!'
2021-01-07,b'$KALA Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline\nhttps://t.co/rXWSqk8LK9'
2021-01-07,b'RT @bUrRpPPP: $KALA Great news...and the cash runway extended to Q4 2022 dang thats almost 2 years!'
2021-01-07,b'RT @egelandd: @spahuja @sheldon6600 @Evofem @JoannaL26896865 @araskopf @Saundraceo Yup- recent $kala estimate without a BO was 47 I believe\xe2\x80\xa6'
2021-01-07,"b""$kala this one offers endless opportunities to add.... so many frustrated retail jump on any pop (can't blame them as they are traders)..... i really get why they might.. it's frustrating stock.  good co. good drug. good ceo."""
2021-01-07,"b""$KALA All the boxes checked now but one.\n\n\xe2\x9c\x85Top Management\n\xe2\x9c\x852 Approved FDA RX\n\xe2\x9c\x85Huge Market/need\n\xe2\x9c\x85Insurance co's on board\n\xe2\x9c\x85First and only RX for acute DED\n\xe2\x9c\x85cash runway extended to Q4 2022\n\xe2\x9c\x85100% De-risked\n\xe2\xac\x9c\xef\xb8\x8f$50 buyout"""
2021-01-07,"b'Midday Most Tweeted Small Caps, check out Gambiste Top 10: $SNDL $CBAT $IDEX $BNGO $GEVO $OCGN $KALA $ORTX $THCB https://t.co/k3uyuEbRpJ'"
2021-01-07,"b'RT @snicobio: @sentivcapital Always liked $KALA, but $ALDX results make me wonder whether there could be consolidation to a single agent in\xe2\x80\xa6'"
2021-01-07,b'RT @bUrRpPPP: $KALA Any remaining uncertainty about insurance coverage has been removed with both HUMANA and AETNA adding Eysuvis to there\xe2\x80\xa6'
2021-01-07,"b'Nice to see the pick of the week #3 $EYPT finally be in the green. I\xe2\x80\x99m considering doing an episode re-hashing all these ophthalmology companies $OCUL, $KALA. What else should I look at?'"
2021-01-07,b'$SUNW $AQMS $KALA \n$DSS $CIIC $ARKG \n$BLCM $SNDL $IPOC\n\xf0\x9f\x93\x88\xf0\x9f\x91\x80\xe2\x9d\x95\nI don\xe2\x80\x99t know about you but I have faith based on facts that it\xe2\x80\x99s going to be a good quarter to own SPACs'
2021-01-07,b'$KALA time to load the boat'
2021-01-07,b'$PULM \n\nNEW #GuruCall \n$43 M Market cap\nMultiple clinical programs in pipeline \n$ARNA $KALA on BoD\nHistory of huge runs in past \n\nFDA update could be coming \xf0\x9f\x94\x9c \n\nExpect 3X Upside \nOver $1.40 will launch \xf0\x9f\x9a\x80 BIG https://t.co/ISgmqjHDUD'
2021-01-07,"b'RT @egelandd: Bioland was sleeping on $kala - it was all there: 2 recently approved products, strong leadership w/execs that have proven M&amp;\xe2\x80\xa6'"
2021-01-07,b'RT @bUrRpPPP: $KALA Any remaining uncertainty about insurance coverage has been removed with both HUMANA and AETNA adding Eysuvis to there\xe2\x80\xa6'
2021-01-07,"b'RT @egelandd: Bioland was sleeping on $kala - it was all there: 2 recently approved products, strong leadership w/execs that have proven M&amp;\xe2\x80\xa6'"
2021-01-07,b'$KALA Any remaining uncertainty about insurance coverage has been removed with both HUMANA and AETNA adding Eysuvis to there 2021 formularies already  clearly they see the cost savings of Eysuvis as needed vs Xiidra junk daily for life...'
2021-01-07,"b'@sentivcapital Always liked $KALA, but $ALDX results make me wonder whether there could be consolidation to a single agent in reproxalap for both the acute and chronic DED settings.'"
2021-01-07,b'$KALA Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline | Business Wire https://t.co/p7Qi7p2g2h'
2021-01-07,"b'$KALA The 2 coming investor conference,s next week will give details about what insurance formulates they were able to get on with such a tight window before the end of 2020... already posters confirming HUMANA and Aentna which are both huge!'"
2021-01-07,"b'Bioland was sleeping on $kala - it was all there: 2 recently approved products, strong leadership w/execs that have proven M&amp;A success, plenty of $$$ (no raises needed) &amp; strong analyst coverage - just let me know when it\xe2\x80\x99s halted for the inevitable BO @ 35+ $ibb $xbi https://t.co/qmIzOQftAk'"
2021-01-07,b'RT @bUrRpPPP: $KALA Buyout news leak?'
2021-01-07,b'$KALA +3.5% (announced the launch of EYSUVIS 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease)  \n\n$WBA +3.4% (to accelerate pace and scale of VillageMD rollout)'
2021-01-07,b'$kala expecting a possible slow launch like most new drugs but q2 is usually good. Still believe bo well before that. Gl longs'
2021-01-07,b'@bUrRpPPP $KALA today is the beginning of a beautiful run https://t.co/klpJlG7e6S'
2021-01-07,"b'@rockzz78 ""Completely agree $kala should be taken out in 2021 &amp; while it would be hard to hate on 3x from current val- I think it will go much higher. I\xe2\x80\x99m also thinking it could be a bidding war between NVS &amp; Abbv that drives the BO val much higher towards true value. $ibb"" from @egelandd'"
2021-01-07,"b""Ooooh, $KALA is going to be up 20 cents today, can't wait for the Twitter experts to proclaim a chart breakout!!!"""
2021-01-07,b'RT @Briefingcom: $KALA: Kala Pharmaceuticals announced the launch of EYSUVIS 0.25% for the short-term (up to two weeks) treatment of... htt\xe2\x80\xa6'
2021-01-07,"b'@rockzz78 ""3 x to 5 x current sp for $kala seems way too conservative given that its two approved products should have combined peak sales approach $1 billion.$4 to $5 billion in a buyout, right? That equates to sp of $70+ to almost $90 based on 56.1m outstanding shs"" from @nalyticsatwork'"
2021-01-07,b'RT @PharmaBoss: $kala I think I found the culprits of who has been keeping the stock price artificially down.  Why would they want to keep\xe2\x80\xa6'
2021-01-07,b'RT @bUrRpPPP: $KALA Great news...and the cash runway extended to Q4 2022 dang thats almost 2 years!'
2021-01-07,b'Anyone have any thoughts on $KALA stock looks like it could be a good swing'
2021-01-07,b'$KALA: Kala Pharmaceuticals announces availability of Eysuvistm for the treatment of dry eye disease and provides... https://t.co/wKDeFD7TPt'
2021-01-07,b'$KALA Buyout news leak?'
2021-01-07,b'$KALA: Kala Pharmaceuticals announced the launch of EYSUVIS 0.25% for the short-term (up to two weeks) treatment of... https://t.co/pTDoDTVidg'
2021-01-07,"b'$kala incredible team ,great value here \xf0\x9f\x98\x8e\xf0\x9f\x98\x8e\xf0\x9f\x98\x8e\xf0\x9f\x98\x8e\xf0\x9f\x98\x8e\xf0\x9f\x98\x8e https://t.co/onstQBu6Rg'"
2021-01-07,b'RT @PharmaBoss: $kala I think I found the culprits of who has been keeping the stock price artificially down.  Why would they want to keep\xe2\x80\xa6'
2021-01-07,b'$KALA Top notch management team executing at lightning speed!'
2021-01-07,"b'along with $KALA, i have buys sitting on $DM $IPOC (adding to positions), eyeing $PLTR to increase holdings there too.  \n\n$NPA looking like a good buy so watching for price action and will likely enter.  \n\n2021 plan working beautifully.'"
2021-01-07,"b'adding to my long position of $KALA today.  this is a triple at least, staying quiet while investors sleep on it.'"
2021-01-07,b'RT @PharmaBoss: $kala I think I found the culprits of who has been keeping the stock price artificially down.  Why would they want to keep\xe2\x80\xa6'
2021-01-07,b'RT @BioStocks: $KALA Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease'
2021-01-07,"b""RT @BioStocks: $KALA expects to report cash, cash equivalents of ~ $153.5M as of Dec'20"""
2021-01-07,b'RT @bUrRpPPP: $KALA $NVS Appears Novartis has pulled it TV ads for Xiidra due to invalid statements contained in the commercial ..they are\xe2\x80\xa6'
2021-01-07,b'$KALA\nKala Pharmaceuticals Launches Dry Eye Disease Therapeutic in US'
2021-01-07,b'$KALA Great news...and the cash runway extended to Q4 2022 dang thats almost 2 years!'
2021-01-07,"b""Congrats to $KALA on the launch of Eysuvis. It's the launch I am watching the closest. Will be challenging, but good mgmt team. Interesting to see a TKI for wAMD being added to (preclinical) pipeline. -&gt; $OCUL $GRAY $EYPT"""
2021-01-07,b'RT @bUrRpPPP: $KALA $NVS Appears Novartis has pulled it TV ads for Xiidra due to invalid statements contained in the commercial ..they are\xe2\x80\xa6'
2021-01-07,b'$kala I think I found the culprits of who has been keeping the stock price artificially down.  Why would they want to keep it down? How about for a more attractive multiplier in a buyout. https://t.co/VJA1YsSbFC'
2021-01-07,"b""$kala ALDX reported stat sig for dry eye disease... muted reaction so far in Pre Market up just a few %.  not sure how relevant this is to Kala.  At best, it's well behind Kala. https://t.co/3MQQwwYliR"""
2021-01-07,b'$KALA Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline https://t.co/i7e1NSodqm'
2021-01-07,b'RT @bUrRpPPP: $KALA $NVS Appears Novartis has pulled it TV ads for Xiidra due to invalid statements contained in the commercial ..they are\xe2\x80\xa6'
2021-01-07,"b'RT @EdgarInsider: Filing Alert, FORM 8-K [Press/News Current Report] available.  $KALA #KalaPharmaceuticals, Inc  https://t.co/9iAACBGmUN'"
2021-01-07,"b'$KALA $NVS Appears Novartis has pulled it TV ads for Xiidra due to invalid statements contained in the commercial ..they are no longer the ""ONLY"" fda approved RX for dry eye.   BUYOUT COMING!'"
2021-01-07,b'RT @BioStocks: $KALA Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease'
2021-01-07,"b""RT @BioStocks: $KALA expects to report cash, cash equivalents of ~ $153.5M as of Dec'20"""
2021-01-07,"b'RT @NicholasCarrInv: Insane how cheap $KALA is here - Launch may have a slow start, but come on. $230m EV?'"
2021-01-07,b'RT @bUrRpPPP: $KALA Eysuvis now available NATIONWIDE!  Wowsa that was fast fast fast! \nhttps://t.co/cRS6XdkheS'
2021-01-07,b'RT @PharmaBoss: $kala Eysuvis is launched. Update on development pipeline. https://t.co/DVZf6xgpwf'
2021-01-07,b'Kala Pharmaceuticals launches Eysuvis for dry eye disease\n$KALA'
2021-01-07,b'$kala Eysuvis is launched. Update on development pipeline. https://t.co/DVZf6xgpwf'
2021-01-07,"b'Insane how cheap $KALA is here - Launch may have a slow start, but come on. $230m EV? https://t.co/EzptF38ZNc'"
2021-01-07,"b'$KALA news.  So Far, so underrated this statement. So underrated on the $NBI. \n\n \xe2\x80\x9cFirst and only prescription therapy approved specifically for short-term treatment of the signs and symptoms of dry eye disease now available in pharmacies nationwide\xe2\x80\x9d'"
2021-01-07,"b""RT @BioStocks: $KALA expects to report cash, cash equivalents of ~ $153.5M as of Dec'20"""
2021-01-07,b'RT @BioStocks: $KALA Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease'
2021-01-07,"b""$KALA expects to report cash, cash equivalents of ~ $153.5M as of Dec'20"""
2021-01-07,b'RT @BioStocks: $KALA Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease'
2021-01-07,b'$KALA Eysuvis now available NATIONWIDE!  Wowsa that was fast fast fast! \nhttps://t.co/cRS6XdkheS'
2021-01-07,"b'@BioStocks Will be interesting at current market cap to see if a suitor emerges. Big opportunity, but questions remain on stand alone launch...No position $KALA'"
2021-01-07,b'$KALA NEW ARTICLE : Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline https://t.co/HwYSmEehna Get all the latest $KALA related news here : https://t.co/HDtEePJHIP https://t.co/x0xYnzxTHu'
2021-01-07,"b'$KALA [15s. delayed]: Issued Press Release on January 07, 07:00:00: Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline https://t.co/lpVqmjZkdk'"
2021-01-07,"b'Filing Alert, FORM 8-K [Press/News Current Report] available.  $KALA #KalaPharmaceuticals, Inc  https://t.co/9iAACBGmUN'"
2021-01-07,"b'$KALA [15s. delayed] filed form 8-K on January 07, 07:02:07: Item2.02: Results of Operations &amp; Financial Condition https://t.co/0XoGUhczGU'"
2021-01-07,"b'$KALA / Kala Pharmaceuticals files form 8-K - Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events -  8-K https://t.co/Ev9ULowt7q'"
2021-01-07,b'$KALA Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline\nhttps://t.co/CtiCpJlr3P'
2021-01-07,b'$KALA Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease'
2021-01-07,b'RT @saltadogato: $KALA interesting background publication on loteprednol etabonate and dry eye (active ingredient in Eyesuvis - although ar\xe2\x80\xa6'
2021-01-07,"b""@saltadogato $KALA  Loteprednol is the steroid used in both Eysuvis and Inveltys  When combined with KALA's Ampplify delivery technology you you can have lower dosing which increases safety and efficacy. Thus no responsible dr will be scripting off label steroids anymore..."""
2021-01-07,b'RT @saltadogato: $KALA interesting background publication on loteprednol etabonate and dry eye (active ingredient in Eyesuvis - although ar\xe2\x80\xa6'
2021-01-07,b'RT @nalyticsatwork: @egelandd @saltadogato @Eli75NY @SettleWilliam guys....Eysuvis is now covered by two of the top payers in the U.S. - Hu\xe2\x80\xa6'
2021-01-07,b'$kala Inveltys is now covered by three major insurers. https://t.co/VoHTsbHyG9'
2021-01-07,b'$KALA interesting background publication on loteprednol etabonate and dry eye (active ingredient in Eyesuvis - although article not about that drug specifically)  https://t.co/oySZeP6kc7'
2021-01-07,b'RT @nalyticsatwork: @egelandd @saltadogato @Eli75NY @SettleWilliam guys....Eysuvis is now covered by two of the top payers in the U.S. - Hu\xe2\x80\xa6'
2021-01-07,"b""@Phoenix3million I once followed ALDX.  I think they have a unique MOA; not sure if their drug is for acute or chronic treatment.  I think they had a disagreement with FDA over which endpoint to use, but ALDX states that has been resolved.  I think they're well-behind $KALA."""
2021-01-07,b'@egelandd @saltadogato @Eli75NY @SettleWilliam guys....Eysuvis is now covered by two of the top payers in the U.S. - Humana and Anthem!  $KALA'
2021-01-07,"b""RT @bUrRpPPP: @egelandd $KALA Eysuvis (loteprednol) is a long proven off label steroid treatment for ded... and now combined with Kala's AM\xe2\x80\xa6"""
2021-01-07,b'$KALA good to see Inveltys on page 84 too!  https://t.co/FPQJDwq5ev'
2021-01-07,"b""$KALA HUGE!  Eysuvis now covered by 3rd largest insurer  Humana.  Humana's covered drug list for 2021 is out and Eysuvis is on page 63...woot woot!  https://t.co/FPQJDwq5ev"""
2021-01-07,"b'Wild day in the markets!  Was up HUGE at one point, ended in the red. \n$CVLB overweight\n$KALA\n$CAPR\n$IPOC warrants \n$SOAC small position warrants \nThat\xe2\x80\x99s all I\xe2\x80\x99m holding \n\nSold my $PCPL warrants today for nice gain \nSold $EBS today very modest gain'"
2021-01-07,"b""$kala ALDX has data out tomorrow morning.  Don't know a lot about ALDX - but it might be useful to keep an eye on the data release prior to open.  Will bad data there act as a tailwind?  or as usual, nothing matters to Kala - trading tightly within 10-20c churn"""
2021-01-06,"b""@egelandd $KALA Eysuvis (loteprednol) is a long proven off label steroid treatment for ded... and now combined with Kala's AMPPLIFY\xc2\xaedrug delivery technology it will quickly become first line RX for fast relief.  Exactly what everyone has been waiting for."""
2021-01-06,b'@bUrRpPPP When you\xe2\x80\x99ve done diligence &amp; know the true val of what ur holding- the daily pps becomes irrelevant- own massive share of $kala at this point &amp; am confident this will be a 5-7X+ return in 2021. Just watch- iwicki is the M&amp;A wizard of biopharma- I bet on ppl not charts $ibb'
2021-01-06,"b""$KALA:\n\nNew Insider Filing on Kala Pharmaceuticals, Inc.'s\n\nChief Medical Officer\n\nROMULUS K BRAZZELL:\n\nhttps://t.co/fegjOGS1mH"""
2021-01-06,b'My current positions are as follows:\n21k $CVLB\n5k $GOEV   Canoo common\n2k $LCY (new position I only got partial full so I didn\xe2\x80\x99t cover this yet)\n1.5k $SOAC (new position partial fill)\n\nbiotech bundle\n15k $AMRN\n12.5k $CHMA\n10k  $EVFM\n2.5k  $GTHX\n10k  $KALA'
2021-01-06,"b""$KALA:\n\nNew Insider Filing on Kala Pharmaceuticals, Inc.'s\n\nChief Financial Officer\n\nMARY REUMUTH:\n\nhttps://t.co/myXDdy1AoB"""
2021-01-06,b'@saltadogato @Eli75NY @nalyticsatwork @SettleWilliam Thx my friend- don\xe2\x80\x99t plan on being wrong on $kala - won\xe2\x80\x99t happen!'
2021-01-06,"b""$KALA:\n\nNew Insider Filing on Kala Pharmaceuticals, Inc.'s\n\nChief Scientific Officer\n\nHONGMING CHEN:\n\nhttps://t.co/cvFjy1clli"""
2021-01-06,b'@Eli75NY @nalyticsatwork @SettleWilliam And I actually think it\xe2\x80\x99s better that it\xe2\x80\x99s not an open buy- doesn\xe2\x80\x99t rule out current late stage M&amp;A activity- $kala will be acquired in 2021 imo or I\xe2\x80\x99ll be happy to delete my Twitter handle &amp; admit I don\xe2\x80\x99t know sh-t about my own industry:) $ibb'
2021-01-06,b'https://t.co/9qmu5kPs8e Kala Pharmaceuticals Inc The AI lets us believe this stock s value has an unfavorable short term setup and has a negative long term outlook $KALA #investment #forex #entrepreneurship'
2021-01-06,"b'As shared- $xair in low 5s was stupid cheap- trimmed in mid 6s since it hasn\xe2\x80\x99t been holding these pops. $urgn sub 18 was silly, $kpti sub 15 was a late Xmas gift, $itci sub 25 insane (now 33.50) &amp; now loading more $gthx 17.50 is dumb &amp; all the $kala I can snag sub 7!! $ibb'"
2021-01-06,"b""@Everlynpdram I'm not in $KALA for the BO, I'm fine with them commercializing , if they get bought out even better. Conservatively speaking a market for Eysuvis of 500M-700M , for a MC of 380M. Even if they don't sell a single prescription they still have cash to operate until late 2022."""
2021-01-06,"b'RT @TahoeLK: Bottom plays;\n$PTGX 19\n$MRNS 12\n$AUPH $13\n$KALA 6.75\n\nNo more downside left with these names. It is like buying $ADAP $4, $BYS\xe2\x80\xa6'"
2021-01-06,b'$kala looks good here'
2021-01-06,"b""$KALA Algo/bots in control now till news. Same 1m shares traded back and forth each day with a few 100k volume from traders... Top Management team not worried about PPS...it will move when it's time... Patience is key here!"""
